Diphydrone en es it fr


Diphydrone Nombres de marca, Diphydrone Analogos

Diphydrone Marca los nombres de mezcla

  • Combunox
  • Percodan-Demi (Acetylsalicylic Acid + Oxycodone Hydrochloride)
  • Pms-Oxycodone - Acetaminophen (Acetaminophen + Oxycodone (Oxycodone Hydrochloride))
  • Rivacocet (Acetaminophen + Oxycodone (Oxycodone Hydrochloride))
  • Roxicet Tab (Acetaminophen + Oxycodone Hydrochloride)
  • Diphydrone Formula quimica


    Diphydrone RX enlace


    Diphydrone FDA hoja

    Diphydrone FDA

    Diphydrone MSDS (hoja de seguridad de materiales)

    Diphydrone MSDS

    Diphydrone Sintesis de referencia

    Pequeños, Lutz, "Química de los alcaloides del opio", Suppl.No.103 (1932)

    Diphydrone Peso molecular

    315.364 g/mol

    Diphydrone Punto de fusion

    218-220 oC

    Diphydrone H2O Solubilidad

    100 mg / ml

    Diphydrone Estado


    Diphydrone LogP


    Diphydrone Formas de dosificacion

    Tableta, supositorio

    Diphydrone Indicacion

    Para el tratamiento de la diarrea, edema pulmonar, para el alivio del dolor moderado a moderadamente grave

    Diphydrone Farmacologia

    Oxicodona, un agonista opiáceo semisintético derivado de la opioides alcaloide, la tebaína, es similar a otros derivados de fenantreno, como la hidrocodona y la morfina. La oxicodona se encuentra disponible en combinación con aspirina o acetaminofén para controlar el dolor y las piernas inquietas y los síndromes de Tourette.

    Diphydrone Absorcion

    absorbe bien en el OxyContin ® comprimidos con una biodisponibilidad oral del 60% al 87%

    Diphydrone Toxicidad

    depresión respiratoria, somnolencia progresando a estupor o coma, flacidez de la musculatura esquelética, piel fría y pegajosa, pupilas, bradicardia, hipotensión y muerte.

    Diphydrone Informacion de Pacientes


    Drug Dependence: Oxycodone can produce drug dependence of the morphine type, and therefore, has the potential for being abused. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of this drug, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, this drug is subject to the Federal Controlled Substances Act.

    Usage in Ambulatory Patients: Oxycodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.

    Interaction with Other Central Nervous System Depressants: Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, other tranquilizers, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with oxycodone hydrochloride may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

    Usage in Pregnancy: Safe use in pregnancy has not been established relative to possible adverse effects on fetal development. Therefore, this drug should not be used in pregnant women unless, in the judgment of the physician, the potential benefits outweigh the possible hazards.

    Usage in Children: This drug should not be administered to children.


    Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

    Acute Abdominal Conditions: The administration of this drug or other narcotics may obscure the diagnosis or clinical course in patients with acute abdominal conditions.

    Special Risk Patients: This drug should be given with caution to certain patients such as the elderly, or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease and prostatic hypertrophy or urethral stricture.

    Diphydrone Organismos afectados

    Humanos y otros mamíferos